Details for New Drug Application (NDA): 217031
✉ Email this page to a colleague
The generic ingredient in MYCOPHENOLATE SODIUM is mycophenolate sodium. There are thirty-eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mycophenolate sodium profile page.
Summary for 217031
| Tradename: | MYCOPHENOLATE SODIUM |
| Applicant: | Biocon Pharma |
| Ingredient: | mycophenolate sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 217031
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MYCOPHENOLATE SODIUM | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 217031 | ANDA | Biocon Pharma Inc. | 70377-126 | 70377-126-11 | 120 TABLET, DELAYED RELEASE in 1 BOTTLE (70377-126-11) |
| MYCOPHENOLATE SODIUM | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 217031 | ANDA | Biocon Pharma Inc. | 70377-127 | 70377-127-11 | 120 TABLET, DELAYED RELEASE in 1 BOTTLE (70377-127-11) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 180MG BASE | ||||
| Approval Date: | Nov 29, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 360MG BASE | ||||
| Approval Date: | Nov 29, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
